XPACE-2005 (also referenced alongside alternative candidate designations like XPACE 2004) is a preclinical prophylactic mRNA vaccine candidate developed by Xanadu Bio Inc.. It is designed to target and protect against Respiratory Syncytial Virus (RSV) infections.